Article snapshot taken from Wikipedia with creative commons attribution-sharealike license.
Give it a read and then ask your questions in the chat.
We can research this topic together.
::This is an updated version of proposed langue for ketamine. All sources are MEDRS complaint with each been peer reviewed and have cited multiple times in other publications. Please feel free to offer opinions or changes. "], an ], has demonstrated rapid-acting antidepressant effects in patients with treatment-resistant major depressive disorder.<ref name="Krystal 2019">{{cite journal |last=Krystal |first=John H. |last2=Abdallah |first2=Chadi G. |last3=Sanacora |first3=Gerard |last4=Charney |first4=Dennis S. |last5=Duman |first5=Ronald S. |title=Ketamine: A Paradigm Shift for Depression Research and Treatment |journal=Neuron |publisher=Elsevier BV |volume=101 |issue=5 |year=2019 |issn=0896-6273 |doi=10.1016/j.neuron.2019.02.005 |pages=774–778 |PMID=30844397}}</ref><ref name="Corriger 2019">{{cite journal |last=Corriger |first=Alexandrine |last2=Pickering |first2=Gisèle |title=Ketamine and depression: a narrative review |journal=Drug Design, Development and Therapy |publisher=Informa UK Limited |volume=13 |year=2019 |issn=1177-8881 |doi=10.2147/dddt.s221437 |pages=3051–3067 |PMID=31695324}}</ref> A nasal spray formulation of ] (Spravato) received FDA approval in March 2019 for the treatment of treatment-resistant depression when used in combination with a conventional antidepressant.<ref name="McIntyre 2021">{{cite journal |last=McIntyre |first=Roger S. |last2=Rosenblat |first2=Joshua D. |last3=Nemeroff |first3=Charles B. |last4=Sanacora |first4=Gerard |last5=Murrough |first5=James W. |last6=Berk |first6=Michael |last7=Brietzke |first7=Elisa |last8=Dodd |first8=Seetal |last9=Gorwood |first9=Philip |last10=Ho |first10=Roger |last11=Iosifescu |first11=Dan V. |last12=Lopez Jaramillo |first12=Carlos |last13=Kasper |first13=Siegfried |last14=Kratiuk |first14=Kevin |last15=Lee |first15=Jung Goo |last16=Lee |first16=Yena |last17=Lui |first17=Leanna M.W. |last18=Mansur |first18=Rodrigo B. |last19=Papakostas |first19=George I. |last20=Subramaniapillai |first20=Mehala |last21=Thase |first21=Michael |last22=Vieta |first22=Eduard |last23=Young |first23=Allan H. |last24=Zarate |first24=Carlos A. |last25=Stahl |first25=Stephen |title=Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation |journal=American Journal of Psychiatry |publisher=American Psychiatric Association Publishing |volume=178 |issue=5 |date=1 May 2021 |issn=0002-953X |doi=10.1176/appi.ajp.2020.20081251 |pages=383–399 |PMID=33726522}}</ref><ref name="Bahr 2019">{{cite journal |last=Bahr |first=R |last2=Lopez |first2=A |last3=Rey |first3=JA |title=Intranasal Esketamine (SpravatoTM) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant |journal=Pharmacy and Therapeutics |volume=44 |issue=6 |year=2019 |pmid=31160868 |pmc=6534172 |pages=340–375}}</ref>" ] (]) 05:50, 21 August 2022 (UTC)
::This is an updated version of proposed langue for ketamine. All sources are MEDRS complaint with each been peer reviewed and have cited multiple times in other publications. Please feel free to offer opinions or changes. "], an ], has demonstrated rapid-acting antidepressant effects in patients with treatment-resistant major depressive disorder.<ref name="Krystal 2019">{{cite journal |last=Krystal |first=John H. |last2=Abdallah |first2=Chadi G. |last3=Sanacora |first3=Gerard |last4=Charney |first4=Dennis S. |last5=Duman |first5=Ronald S. |title=Ketamine: A Paradigm Shift for Depression Research and Treatment |journal=Neuron |publisher=Elsevier BV |volume=101 |issue=5 |year=2019 |issn=0896-6273 |doi=10.1016/j.neuron.2019.02.005 |pages=774–778 |PMID=30844397}}</ref><ref name="Corriger 2019">{{cite journal |last=Corriger |first=Alexandrine |last2=Pickering |first2=Gisèle |title=Ketamine and depression: a narrative review |journal=Drug Design, Development and Therapy |publisher=Informa UK Limited |volume=13 |year=2019 |issn=1177-8881 |doi=10.2147/dddt.s221437 |pages=3051–3067 |PMID=31695324}}</ref> A nasal spray formulation of ] (Spravato) received FDA approval in March 2019 for the treatment of treatment-resistant depression when used in combination with a conventional antidepressant.<ref name="McIntyre 2021">{{cite journal |last=McIntyre |first=Roger S. |last2=Rosenblat |first2=Joshua D. |last3=Nemeroff |first3=Charles B. |last4=Sanacora |first4=Gerard |last5=Murrough |first5=James W. |last6=Berk |first6=Michael |last7=Brietzke |first7=Elisa |last8=Dodd |first8=Seetal |last9=Gorwood |first9=Philip |last10=Ho |first10=Roger |last11=Iosifescu |first11=Dan V. |last12=Lopez Jaramillo |first12=Carlos |last13=Kasper |first13=Siegfried |last14=Kratiuk |first14=Kevin |last15=Lee |first15=Jung Goo |last16=Lee |first16=Yena |last17=Lui |first17=Leanna M.W. |last18=Mansur |first18=Rodrigo B. |last19=Papakostas |first19=George I. |last20=Subramaniapillai |first20=Mehala |last21=Thase |first21=Michael |last22=Vieta |first22=Eduard |last23=Young |first23=Allan H. |last24=Zarate |first24=Carlos A. |last25=Stahl |first25=Stephen |title=Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation |journal=American Journal of Psychiatry |publisher=American Psychiatric Association Publishing |volume=178 |issue=5 |date=1 May 2021 |issn=0002-953X |doi=10.1176/appi.ajp.2020.20081251 |pages=383–399 |PMID=33726522}}</ref><ref name="Bahr 2019">{{cite journal |last=Bahr |first=R |last2=Lopez |first2=A |last3=Rey |first3=JA |title=Intranasal Esketamine (SpravatoTM) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant |journal=Pharmacy and Therapeutics |volume=44 |issue=6 |year=2019 |pmid=31160868 |pmc=6534172 |pages=340–375}}</ref>" ] (]) 05:50, 21 August 2022 (UTC)
This article is within the scope of WikiProject Psychology, a collaborative effort to improve the coverage of Psychology on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PsychologyWikipedia:WikiProject PsychologyTemplate:WikiProject Psychologypsychology
This article is within the scope of WikiProject Neuroscience, a collaborative effort to improve the coverage of Neuroscience on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.NeuroscienceWikipedia:WikiProject NeuroscienceTemplate:WikiProject Neuroscienceneuroscience
This article is part of the History of Science WikiProject, an attempt to improve and organize the history of science content on Misplaced Pages. If you would like to participate, you can edit the article attached to this page, or visit the project page, where you can join the project and/or contribute to the discussion. You can also help with the History of Science Collaboration of the Month.History of ScienceWikipedia:WikiProject History of ScienceTemplate:WikiProject History of Sciencehistory of science
This article is within the scope of WikiProject Molecular Biology, a collaborative effort to improve the coverage of Molecular Biology on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Molecular BiologyWikipedia:WikiProject Molecular BiologyTemplate:WikiProject Molecular BiologyMolecular Biology
This article is within the scope of WikiProject Death, a collaborative effort to improve the coverage of Death on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.DeathWikipedia:WikiProject DeathTemplate:WikiProject DeathDeath
This article is within the scope of WikiProject Women's Health, a collaborative effort to improve the coverage of Women's Health on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Women's HealthWikipedia:WikiProject Women's HealthTemplate:WikiProject Women's Healthwomen's health
This article is of interest to WikiProject LGBTQ+ studies, which tries to ensure comprehensive and factual coverage of all LGBTQ-related issues on Misplaced Pages. For more information, or to get involved, please visit the project page or contribute to the discussion.LGBTQ+ studiesWikipedia:WikiProject LGBTQ+ studiesTemplate:WikiProject LGBTQ+ studiesLGBTQ+ studies
Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.
Major depressive disorder is within the scope of WikiProject Disability. For more information, visit the project page, where you can join the project and/or contribute to the discussion.DisabilityWikipedia:WikiProject DisabilityTemplate:WikiProject DisabilityDisability
This article is written in American English, which has its own spelling conventions (color, defense, traveled) and some terms that are used in it may be different or absent from other varieties of English. According to the relevant style guide, this should not be changed without broad consensus.
Very little is said in the article about the psychosocial factors that may play a role in the development of a major depressive disorder. I hope somebody with more knowledge than me on the subject can improve the article with this info. --Savig (talk) 08:35, 15 June 2022 (UTC)
Other terms related to major depressive disorder/episodes.
I have found other terms related to major depressive disorder/episodes. I thought that they could be included in this article to increase the scope of MDD but somebody says that none of them belong here and that the article is already too long, even though there are articles that are even longer . The list of other terms are:
... section is getting stubby ... lots of short paragraphs and information that needs to be merged or possibly removed. I see student editing here. (Also found info chunked in to the lead that was nowhere in the body, so fixed that.) SandyGeorgia (Talk) 18:50, 17 August 2020 (UTC)
Elderly
This section looks also like it was chunked in as an afterthought. It duplicates some management information, which can be merged to Management or deleted, and the rest of it can go within the other sections as appropriate (prognosis or epidemiology?). SandyGeorgia (Talk) 19:08, 17 August 2020 (UTC)
Out of whack, and looks like people are just chunking in random factoids here, rather than following WP:WIAFA. "There has been a continuing discussion of whether neurological disorders and mood disorders may be linked to creativity," has WHAT to do with stigma? The section is not very well written. SandyGeorgia (Talk) 19:13, 17 August 2020 (UTC)
That section dates right back to the FAC. I can see it there almost unchanged in December 2008. So I think I might be the guilty party on that one. :P - I do think we need to do something about the length of the article and updating etc. Am looking now.Cas Liber (talk·contribs) 01:20, 18 August 2020 (UTC)
Resurrecting this from the archive, as this is now the longest standing medicine-related FA at Misplaced Pages:Featured article review/notices given. Sandy and Casliber, how do you feel about the article's current state? If you're pleased with changes, I can remove it from the template. If not, I can try to whip up some volunteers to plug away at any deficiencies. All else fails, we can start the WP:FAR process. Thanks for all your work on this! -- and of course thanks to Casliber for doing the heavy lifting to bring this to FA condition almost 13 years ago. I hope you're both doing well. Ajpolino (talk) 14:47, 8 August 2021 (UTC)
@Ajpolino: I think the article needs some cleanup. I've mostly been looking at unclear/inelegant prose today, but I intend look into Sandy's content concerns soon. Haven't gotten through the whole article yet, but the "Pathophysiology" section, for one, seems overly detailed. Cheers, Ovinus (talk) 00:39, 25 September 2021 (UTC)
What I'm doing is comparing the current version to this which was soon after it was promoted and near time it was mainpaged. Just to compare the prose and scope mainly. However, the data needs to be updated to latest studies. I've begun adjusting the prose a bit. Work in progress....Cas Liber (talk·contribs) 14:16, 25 September 2021 (UTC)
Basic Problems of this Article
Hi, I was studying this article that I realized there were many sentences that do not have a reference. Also, the references were not added to the article alike, some one are sfn and others are not. Many parts need to be updated and the article is not comprehensive. I do not know how this article was Featured but must not be Featured now. Pereoptic09:29, 13 August 2022 (UTC)
I can't find a single unsourced paragraph in this entire article, are they any concrete instances you can point out where a source would be needed but is lacking? I ask the same for what you think needs updating and what information is missing.--Megaman en m (talk) 11:21, 13 August 2022 (UTC)
Likewise, where is the specific uncited text? Every sentence does not need to be cited; the reference may after a subsequent sentence. SandyGeorgia (Talk) 15:42, 13 August 2022 (UTC)
@Megaman en m:For example, the first paragraph of the management section, the second paragraph of Antidepressants.
@SandyGeorgia: The main problems I mentioned in the article were not the only one. To the things I mentioned above, add the short introduction of the article and Having a reference in the introduction.
Issues not covered in the article: , In the pathophysiology section, it is also possible to discuss the relationship between major depression and chronic diseases
The first paragraph of management clearly references the NICE guidelines, which are cited at the end of that para (including the bullet points). The second paragraph of antidepressants is cited, so I'm unsure if I'm looking somewhere different than you are ?? The size of the lead is fine, and citations in the lead are neither required nor discouraged; I see no problem there. Could you please provide a PMID or description of what you consider not covered, so others don't have to click on each little bracketed number to see the concern? It would help, thanks. Casliber I am wearying of being the only person maintaining this article. Can we get it updated or else move to the next step? I am swamped, and yet here I am, trying to click on little numbers to figure out what is wanted next. SandyGeorgia (Talk) 20:51, 13 August 2022 (UTC)
Joyous it is not, and I'm really tired of it; we need committed FA-knowledgeable editors to keep this article updated. Are the 2004 NICE guidelines the latest? SandyGeorgia (Talk) 21:53, 13 August 2022 (UTC)
This reference to ==> Cause and Prognosis (for example generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, and social anxiety disorder and poor treatment outcomes)
I think this reference is considered a secondary review, because at the end of it, the bibliography section is placed. In addition, its source is the American Psychiatric Association. Pereoptic13:09, 14 August 2022 (UTC)
I'm not using a source like that in a Featured article; an alternate approach to adding whatever content you wish to include is to see if any of the sources listed at the end of that article are secondary reviews, and use them. SandyGeorgia (Talk) 15:09, 14 August 2022 (UTC)
I will mention the shortcomings of the article's introduction in the future. My written English grammar is a little weak, otherwise I would have added the required content to the article myself. Pereoptic09:27, 14 August 2022 (UTC)
I'm willing to help do the updates as I have time, but I can get to things faster if you provide MEDRS sources and if I don't have to do all the citation formatting (see above). Do you have the tool for citing PMIDs used in this article? Or you can use the PMID template followed by a bracket and the number for easier reference. For today, I have to finish work on another Featured article, so perhaps someone else will get to them faster. Spicy have you any interest in helping maintain this FA? I don't have time to get to it today, and two updates needed are identified above. SandyGeorgia (Talk) 11:45, 14 August 2022 (UTC)
Laishley EJ, Barrett AM, Isaac O, Thiemer K, Jariwalla R, Grossberg SE, Sedmak JJ, Anderson TR, Slotkin TA (November 1975). "Regulation and properties of an invertase from Clostridium pasteurianum". Can J Microbiol. 21 (11): 1711–8. doi:10.1139/m75-251. PMID140. to ==> CausePereoptic13:22, 14 August 2022 (UTC)
Better :) I can attempt to work on some of this over time, but for the next few days, I am up to my eyeballs at the Joan of ArcFeatured article review, and must stay focused on getting that wrapped up. I'm hoping someone else will jump in here to help ... what is listed so far does not look insurmountable. SandyGeorgia (Talk) 18:54, 14 August 2022 (UTC)
I hope you will be successful in improving the above article. There is no rush, we will improve the article as time permits. I will also try to add things to the article over time, although it needs to be checked grammatically by an English speaker. Sincerely Pereoptic20:28, 14 August 2022 (UTC)
Urgent FAR needed
I am one person and cannot maintain this old FA alone, and will no longer endure the demoralization of trying to do so. This is one of the oldest listed at WP:FARGIVEN, and my recommendation is that someone submit it urgently to WP:FAR. SandyGeorgia (Talk) 14:36, 18 August 2022 (UTC)
Esketamine as treatment for MDD
@SandyGeorgia removed my edits concerning the use of esketamine as a treatment for depression (as well as a reference to an FDA press release stating that it had been approved) and stated that I needed to obtain a secondary source and discuss this on the talkpage. Spravato is an FDA-approved intranasal formulation of esketamine with an indication for treatment resistant depression when combined with an oral antidepressant. I think that this is an important treatment modality that should be listed with other treatments for depression. There are many high-quality, WP:MEDRS complaint sources that are about Spravato that are readily available. Examples of peer reviewed MEDRS sources include PMID32729898 and PMID32163257. While on the topic of ketamine for depression, I feel that it could be worthwhile to discuss racemic ketamine as a treatment like the management of depression has, although this is not currently FDA approved for this indication. In closing, I feel there should be a mention of esketamine in the treatment section of the article and possibly also about ketamine in general. Thanks. Wikipedialuva (talk) 00:38, 20 August 2022 (UTC)
I am very open to how it would be phrased. An example text might be: "A nasal spray formulation of the NMDA receptor antagonistesketamine, sold under the brand name Spravato, gained FDA approval in 2019 for the treatment of treatment-resistant depression when combined with an oral antidepressant." Wikipedialuva (talk) 02:35, 20 August 2022 (UTC) Wikipedialuva (talk) 02:35, 20 August 2022 (UTC)
This is an updated version of proposed langue for ketamine. All sources are MEDRS complaint with each been peer reviewed and have cited multiple times in other publications. Please feel free to offer opinions or changes. "Ketamine, an NMDA receptor antagonist, has demonstrated rapid-acting antidepressant effects in patients with treatment-resistant major depressive disorder. A nasal spray formulation of esketamine (Spravato) received FDA approval in March 2019 for the treatment of treatment-resistant depression when used in combination with a conventional antidepressant." Wikipedialuva (talk) 05:50, 21 August 2022 (UTC)
References
References
Jalloh, Mohamed (15 March 2020). "Esketamine (Spravato) for Treatment-Resistant Depression". American Family Physician. 101 (6): 339–340. ISSN0002-838X. PMID32163257.
Sanders, Benjamin; Brula, Abdul Q. (2021). "Intranasal esketamine: From origins to future implications in treatment-resistant depression". Journal of Psychiatric Research. 137. Elsevier BV: 29–35. doi:10.1016/j.jpsychires.2021.02.020. ISSN0022-3956. PMID33647726.
Krystal, John H.; Abdallah, Chadi G.; Sanacora, Gerard; Charney, Dennis S.; Duman, Ronald S. (2019). "Ketamine: A Paradigm Shift for Depression Research and Treatment". Neuron. 101 (5). Elsevier BV: 774–778. doi:10.1016/j.neuron.2019.02.005. ISSN0896-6273. PMID30844397.
Corriger, Alexandrine; Pickering, Gisèle (2019). "Ketamine and depression: a narrative review". Drug Design, Development and Therapy. 13. Informa UK Limited: 3051–3067. doi:10.2147/dddt.s221437. ISSN1177-8881. PMID31695324.{{cite journal}}: CS1 maint: unflagged free DOI (link)
McIntyre, Roger S.; Rosenblat, Joshua D.; Nemeroff, Charles B.; Sanacora, Gerard; Murrough, James W.; Berk, Michael; Brietzke, Elisa; Dodd, Seetal; Gorwood, Philip; Ho, Roger; Iosifescu, Dan V.; Lopez Jaramillo, Carlos; Kasper, Siegfried; Kratiuk, Kevin; Lee, Jung Goo; Lee, Yena; Lui, Leanna M.W.; Mansur, Rodrigo B.; Papakostas, George I.; Subramaniapillai, Mehala; Thase, Michael; Vieta, Eduard; Young, Allan H.; Zarate, Carlos A.; Stahl, Stephen (1 May 2021). "Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation". American Journal of Psychiatry. 178 (5). American Psychiatric Association Publishing: 383–399. doi:10.1176/appi.ajp.2020.20081251. ISSN0002-953X. PMID33726522.